Table 3.
Response rates at different time points after switching.
| Items | Total | Eltrombopag group | Rh-TPO group | χ2 | P-value | ||
| The inefficacy group | N = 49 | N = 27 | N = 22 | ||||
| 6 weeks | CR+R, n (%) | 13+8 (43%) | 7+2 (33%) | 6+6 (55%) | 2.227 | 0.14∗ | |
| NR, n (%) | 28 (57%) | 18 (67%) | 10 (45%) | ||||
| 3 months | CR+R, n (%) | 12+10 (45%) | 9+3 (44%) | 3+7 (45%) | 0.005 | 0.94∗ | |
| NR, n (%) | 27 (55%) | 15 (56%) | 12 (55%) | ||||
| 6 months | CR+R, n (%) | 13+11 (49%) | 9+4 (48%) | 4+7 (50%) | 0.017 | 0.90∗ | |
| NR, n (%) | 25 (51%) | 14 (52%) | 11 (50%) | ||||
| The non-efficacy-related group | N=47 | N=26 | N=21 | ||||
| 6 weeks | CR+R, n (%) | 16+18 (72%) | 14+7 (81%) | 2+11 (62%) | 2.066 | 0.15∗ | |
| NR, n (%) | 13 (28%) | 5 (19%) | 8 (38%) | ||||
| 3 months | CR+R, n (%) | 20+18 (81%) | 17+5 (85%) | 3+13 (76%) | – | 0.49† | |
| NR, n (%) | 9 (19%) | 4 (15%) | 5 (24%) | ||||
| 6 months | CR+R, n (%) | 18+19 (79%) | 16+6 (85%) | 2+13 (71%) | – | 0.31† | |
| NR, n (%) | 10 (21%) | 4 (15%) | 6 (29%) |
∗
Pearson χ2 test.
†
Fisher's exact test.
CR: Complete response; NR: Nonresponse; R: Response; rh-TPO: Recombinant human thrombopoietin.